Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesACRUX Ltd

ACRUX Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.009 AUD -0.00 ( 10.00%)
Last update at 2026-11-06T05:10:00Z
VOLUME
1679748
Market Cap
6.12M

Momentum Score

…

Acrux Limited, together with its subsidiaries, develops and commercializes topically applied pharmaceutical products in Australia, the United States, Europe, and internationally. The company offers Dapsone 7.5% and 5% gels for the treatment of acne vulgaris; Nitroglycerine 0.4% ointments for the treatment of moderate to severe pain associated with chronic anal fissure; Lidocaine and Prilocaine creams USP 2.5% for local analgesia and pre-treatment for infiltration anesthesia; and estradiol transdermal sprays for women for the treatment of moderate to severe hot flushes associated with menopause under the Lenzetto and Evamist brand names. It also provides laboratory and product development services, including in vitro release testing; formulation development; stability and quality check; analytical; generic and pharma development; regulatory; project management and technology transfer; consulting; and co-development services. The company was incorporated in 1998 and is based in West Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
0.01
Low
0.02
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Acrux Limited is an Australian specialty pharmaceutical company focused on topical and transdermal drug delivery for hormonal and dermatological treatments. Its long-term growth drivers include advancing clinical programs and regulatory approvals, securing licensing or commercialization partnerships, and scaling manufacturing for any marketed products, which may benefit investors seeking exposure to delivery-technology-focused therapeutics.

Key investment risks include clinical and regulatory failure, reliance on a limited product pipeline and external partners for commercialization, potential funding or cash-flow constraints, and patent or competitive pressures.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
6.58M
Revenue Per Share
0.02
Gross Profit TTM
5.54M
Debt / Equity
1.72
ROE
-48.51%
Net Debt
0.81M
ROCE
-55.88%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -2.41M -5.94M -5.57M -0.21M -9.58M
Net income -0.60M -5.95M -5.80M -0.76M -9.83M
Selling general administrative 4.85M 5.77M 5.77M 5.77M 6.08M
Selling and marketing expenses - - 5.58M - -
Gross profit 4.21M 1.19M 1.13M 7.87M -4.65M
Reconciled depreciation 0.44M 0.47M 0.51M 0.59M 0.66M
Ebit -2.14M -5.63M -8.57M -3.07M -12.97M
Ebitda -1.70M -5.17M -8.06M -2.47M -12.31M
Depreciation and amortization 0.44M 0.47M 0.51M 0.59M 0.66M
Operating income -2.14M -8.97M -8.57M -3.39M -12.97M
Other operating expenses 6.78M 10.16M 13.67M 8.76M 11.32M
Interest expense 0.28M 0.30M - - 0.02M
Tax provision 0.14M 0.01M 0.23M 0.55M 0.25M
Interest income 0.01M 0.04M 0.13M 0.12M 0.02M
Net interest income -0.27M -0.26M 0.13M 0.12M 0.02M
Income tax expense -1.80M 0.01M 0.23M 0.55M 0.25M
Total revenue 4.64M 1.19M 5.09M 8.43M 1.72M
Total operating expenses 6.34M 10.16M 9.71M 11.26M 14.69M
Cost of revenue 0.44M 0.47M 3.96M 0.56M 6.37M
Total other income expense net -0.27M 3.04M 3.01M 3.06M 3.37M
Net income from continuing ops -0.60M -5.95M -5.80M -0.76M -9.83M
Net income applicable to common shares - -5.95M -5.80M -0.76M -9.83M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 6.82M 7.22M 9.95M 13.29M 14.30M
Intangible assets - - - 0.00M 0.38M
Other current assets 0.03M - 0.15M 0.04M 3.92M
Total liab 5.36M 6.20M 6.68M 4.59M 5.21M
Total stockholder equity 1.47M 1.02M 3.28M 8.70M 9.09M
Deferred long term liab - - - - 0.38M
Other current liab 1.01M - 1.51M 1.90M 2.53M
Common stock 119.25M - 115.01M 114.88M 114.56M
Capital stock 119.25M 118.22M - 114.88M 114.56M
Retained earnings -126.84M -126.23M -120.29M -114.49M -113.72M
Other liab - - - 0.04M 0.04M
Other assets - - - 0.80M 1.73M
Cash 1.71M 0.86M 2.94M 6.23M 5.83M
Cash and equivalents - - - 3.00M 3.00M
Total current liabilities 3.00M 4.48M 3.72M 2.39M 3.32M
Current deferred revenue 0.07M - - -0.19M -0.22M
Net debt 0.81M 0.86M 0.76M -3.88M -3.75M
Short term debt 1.19M - 1.78M 0.19M 0.22M
Short long term debt 0.95M 1.73M - - -
Short long term debt total 2.52M - 3.70M 2.35M 2.08M
Other stockholder equity - - - 0.91M 0.86M
Property plant equipment - - - 2.59M 2.56M
Total current assets 4.11M 4.80M 5.98M 9.89M 10.02M
Net tangible assets - - - 8.70M 9.09M
Net receivables 2.37M 0.72M 2.89M 3.31M 3.77M
Inventory - - - 0.32M 0.00M
Accounts payable 0.73M 0.46M 0.43M 0.49M 0.79M
Accumulated other comprehensive income 9.05M - 8.55M 8.30M 8.25M
Non currrent assets other - - - - -2.56M
Non current assets total 2.72M 2.42M 3.97M 3.39M 4.29M
Capital lease obligations 1.57M 1.91M - 2.35M 2.08M
Long term debt total - - - 2.16M 1.85M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -0.01M -0.28M -0.12M -0.47M
Change to liabilities - - - -0.29M 0.69M
Total cashflows from investing activities - -0.01M -0.28M -0.12M -0.47M
Net borrowings -0.78M 0.23M 1.49M -0.18M -0.15M
Total cash from financing activities -0.18M 3.39M 1.29M -0.18M -0.15M
Change to operating activities - - - 0.02M -0.18M
Net income -0.60M -5.95M -5.80M -0.76M -9.83M
Change in cash 0.84M -2.08M -3.29M 0.40M -9.44M
Begin period cash flow 0.86M 2.94M 6.23M 5.83M 15.27M
End period cash flow 1.71M 0.86M 2.94M 6.23M 5.83M
Total cash from operating activities 1.02M -5.47M -4.30M 0.70M -8.82M
Issuance of capital stock 0.87M 3.38M - - -
Depreciation 0.44M - 0.51M 0.86M 0.55M
Change to account receivables 1.42M -0.90M 0.42M 0.46M -0.61M
Sale purchase of stock - - - - 0.00M
Other cashflows from financing activities -0.27M -0.22M -0.20M -0.12M -0.47M
Change to netincome - - - 0.37M 0.45M
Capital expenditures 0.00M 0.01M 0.28M 0.12M 0.47M
Change in working capital 1.00M -0.21M 0.67M 0.46M -0.61M
Stock based compensation - - 0.38M 0.37M 0.45M
Other non cash items 0.18M -5.26M -0.06M 0.60M 0.46M
Free cash flow 1.02M -5.48M -4.58M 0.58M -9.28M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ACR
ACRUX Ltd		 -0.00
10.00%		 0.01 - 11.60 0.93 4.17 1.61 27.63
CSL
CSL Ltd		 -0.36
0.18%		 202.04 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.41
2.91%		 13.67 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -
-%		 23.24 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.14
6.45%		 2.03 - 454.55 23.43 3.36 18.28 -9.86

Profile*

ACRUX Ltd

Acrux Limited, together with its subsidiaries, develops and commercializes topically applied pharmaceutical products in Australia, the United States, Europe, and internationally. The company offers Dapsone 7.5% and 5% gels for the treatment of acne vulgaris; Nitroglycerine 0.4% ointments for the treatment of moderate to severe pain associated with chronic anal fissure; Lidocaine and Prilocaine creams USP 2.5% for local analgesia and pre-treatment for infiltration anesthesia; and estradiol transdermal sprays for women for the treatment of moderate to severe hot flushes associated with menopause under the Lenzetto and Evamist brand names. It also provides laboratory and product development services, including in vitro release testing; formulation development; stability and quality check; analytical; generic and pharma development; regulatory; project management and technology transfer; consulting; and co-development services. The company was incorporated in 1998 and is based in West Melbourne, Australia.

103-113, Stanley Street, West Melbourne, VIC, Australia, 3003

61 3 8379 0100

https://acrux.com.au

Name Title Year Born
Mr. Michael John Kotsanis B.Sc., BSc, GradDipBus, MBus CEO, MD & Exec. Director 1966
Ms. Joanna Johnson B.E., BEc, ICAA CFO & Company Sec. NA
Ms. Felicia Colagrande B.Sc., BSc (Hons), M.B.A., MBA Product Devel. & Technical Affairs Director NA
Mr. Charles O'Sullivan B. Pharm Portfolio Director NA
Mr. Mark Hyman Project & Technical Devel. Director NA
Mr. Michael John Kotsanis B.Sc., BSc, GradDipBus, MBus CEO, MD & Executive Director 1966
Ms. Joanna Johnson B.E., BEc, ICAA CFO & Company Secretary NA
Mr. Michael John Kotsanis B.Sc., BSc, GradDipBus, MBus CEO, MD & Executive Director 1966
Ms. Joanna Johnson B.E., BEc, ICAA CFO & Company Secretary NA
Mr. Michael John Kotsanis B.Sc., BSc, GradDipBus, MBus CEO, MD & Executive Director 1966

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…